NCT01731249 - Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis | Biotech Hunter

Enrollment

574

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

October 31, 2012

Conditions

HypersensitivityAllergic RhinitisAllergic ConjunctivitisSeasonal Allergy

Interventions

BIOLOGICAL

Placebo

10 actuations of placebo sublingual solution once daily 5 months a year and during 2 years

BIOLOGICAL

Birch pollen allergen extract

Sublingual solution of Birch pollen allergen extract 300IR (10 actuations) once daily 5 months per year and during 2 years

Trial Locations (11)

Centre of Investigations and Treatment of Allergic Diseases, Riga

National University Hospital - Allergy Unit 4222, Copenhagen

Universitätsmedizin Berlin - Allergie-Centrum-Charité, Berlin

Merekivi Perearstid OÜ, Tallinn

Alergologicka ordinace, Pilsen

NHC, Hôpitaux Universitaires de Strasbourg, Strasbourg

Helsingin yliopistollinen keskussairaala, Helsinki

Allergic Diseases Diagnostics and Treatment Centre, Vilnius

SPZOZ Uniwersytecki Szpital Kliniczny Nr 1im.N.Barlickiego w Uniwersystetu Medycznego w Łodzi, Lodz

Imunologicko-alergologicka amb., Banská Bystrica

Sahlgrenska Universitetssjukhuset - Avd för Lungmedicin och Allergi, Gothenburg